JW (Cayman) Therapeutics Co. Ltd

SEHK:2126 Stock Report

Market Cap: HK$912.4m

JW (Cayman) Therapeutics Past Earnings Performance

Past criteria checks 0/6

JW (Cayman) Therapeutics has been growing earnings at an average annual rate of 0.4%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 70.6% per year.

Key information

0.4%

Earnings growth rate

42.1%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate70.6%
Return on equity-45.6%
Net Margin-441.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

A Piece Of The Puzzle Missing From JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) 34% Share Price Climb

May 10
A Piece Of The Puzzle Missing From JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) 34% Share Price Climb

Calculating The Intrinsic Value Of JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

May 03
Calculating The Intrinsic Value Of JW (Cayman) Therapeutics Co. Ltd (HKG:2126)

JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?

Feb 03
JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?

Revenue & Expenses Breakdown

How JW (Cayman) Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:2126 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23174-768253414
30 Sep 23171-783294421
30 Jun 23167-797334428
31 Mar 23157-822352418
31 Dec 22146-846371408
30 Sep 22121-849383416
30 Jun 2297-851396425
31 Mar 2264-777384420
31 Dec 2131-702372414
30 Sep 2115-998344371
30 Jun 21-1-1,294315328
31 Mar 210-1,479280277
31 Dec 200-1,664245225
30 Sep 203-1,295186195
30 Jun 206-925128164
31 Mar 206-779101150
31 Dec 195-63373136
31 Dec 180-2734176

Quality Earnings: 2126 is currently unprofitable.

Growing Profit Margin: 2126 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2126 is unprofitable, but has reduced losses over the past 5 years at a rate of 0.4% per year.

Accelerating Growth: Unable to compare 2126's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2126 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).


Return on Equity

High ROE: 2126 has a negative Return on Equity (-45.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.